Case report: diagnosis of VEXAS syndrome in a patient with therapy-resistant large vessel vasculitis

References

• Beck DB, Ferrada MA, Sikora KA, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020;383(27):2628–38. doi: 10.1056/NEJMoa2026834
   PubMed Web of Science ®Google Scholar
• Grayson PC, Beck DB, Ferrada MA, et al. VEXAS syndrome and disease taxonomy in rheumatology. Arthritis & Rheumat. 2022;74(11):1733–6. doi: 10.1002/art.42258
   PubMed Web of Science ®Google Scholar
• Barba T, Jamilloux Y, Durel CA, et al. VEXAS syndrome in a woman. Rheumatology (Oxford). 2021;60(11):e402–e3. doi: 10.1093/rheumatology/keab392
   PubMed Web of Science ®Google Scholar
• Stubbins RJ, McGinnis E, Johal B, et al. VEXAS syndrome in a female patient with constitutional 45,X (turner syndrome). Haematologica. 2022;107(4):1011–1013. doi: 10.3324/haematol.2021.280238
   PubMed Web of Science ®Google Scholar
• Georgin-Lavialle S, Terrier B, Guedon AF, et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 2022;186(3):564–74. doi: 10.1111/bjd.20805
   PubMed Web of Science ®Google Scholar
• Ferrada MA, Savic S, Cardona DO, et al. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood. 2022;140(13):1496–506. doi: 10.1182/blood.2022016985
   PubMed Web of Science ®Google Scholar
• Watanabe R, Kiji M, Hashimoto M. Vasculitis associated with VEXAS syndrome: a literature review. Front Med. 2022;9:983939. doi: 10.3389/fmed.2022.983939
   Web of Science ®Google Scholar
• Midtvedt Ø, Stray-Pedersen A, Andersson H, et al. A man in his sixties with chondritis and bone marrow failure. Tidsskr Nor Laegeforen. 2022;142(4). doi: 10.4045/tidsskr.21.0370
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Kobayashi D, Nakamura G, et al. Acute heart failure due to left common iliac arteriovenous fistula: a case of VEXAS syndrome. Mod Rheumatol Case Rep. 2023;7(1):327–333. doi: 10.1093/mrcr/rxac082
   PubMedGoogle Scholar
• Grayson PC, Patel BA, Young NS. VEXAS syndrome. Blood. 2021;137(26):3591–4. doi: 10.1182/blood.2021011455
   PubMed Web of Science ®Google Scholar
• Obiorah IE, Patel BA, Groarke EM, et al. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv. 2021;5(16):3203–3215. doi: 10.1182/bloodadvances.2021004976
   PubMed Web of Science ®Google Scholar
• Bourbon E, Heiblig M, Gerfaud Valentin M, et al. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood. 2021;137(26):3682–4. doi: 10.1182/blood.2020010177
   PubMed Web of Science ®Google Scholar
• Heiblig M, Patel BA, Groarke EM, et al. Toward a pathophysiology inspired treatment of VEXAS syndrome. Semin Hematol. 2021;58(4):239–46. doi: 10.1053/j.seminhematol.2021.09.001
   PubMed Web of Science ®Google Scholar
• Boyadzhieva Z, Ruffer N, Kötter I, et al. How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Rheumatology (Oxford). 2023;62(11):3518–25. doi: 10.1093/rheumatology/kead240
   PubMed Web of Science ®Google Scholar
• Kunishita Y, Kirino Y, Tsuchida N, et al. Case report: tocilizumab treatment for VEXAS syndrome with relapsing polychondritis: a single-center, 1-year longitudinal observational study in Japan. Front Immunol. 2022;13:901063. doi: 10.3389/fimmu.2022.901063
   PubMed Web of Science ®Google Scholar
• van der Made CI, Potjewijd J, Hoogstins A, et al. Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of patients with VEXAS. J Allergy Clin Immunol. 2022;149(1):432–9.e4. doi: 10.1016/j.jaci.2021.05.014
   PubMed Web of Science ®Google Scholar
• Heiblig M, Ferrada MA, Koster MJ, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 2022;140(8):927–931. doi: 10.1182/blood.2022016642
   PubMed Web of Science ®Google Scholar
• Diarra A, Duployez N, Fournier E, et al. Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv. 2022;6(3):998–1003. doi: 10.1182/bloodadvances.2021004749
   PubMed Web of Science ®Google Scholar
• Al-Hakim A, Poulter JA, Mahmoud D, et al. Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience. Br J Haematol. 2022;199(5):777–81. doi: 10.1111/bjh.18488
   PubMed Web of Science ®Google Scholar